Sumitomo Pharma revenue and financials

4506 · TSE · JPY

¥1,621.00+2.66%+¥42.00

Close · October 6, 2026

In the fiscal year ended March 2026, Sumitomo Pharma reported revenue of ¥453.29B (+13.66% year over year). Net income was ¥106.87B, a net margin of 23.6%.

Annual revenue · 2026: ¥453.29B
  1. ¥555.54B2023
  2. ¥314.56B2024
  3. ¥398.83B2025
  4. ¥453.29B2026

Fiscal year ending in March. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
+13.66%
FY to Mar 2026 vs FY to Mar 2025
Net income growth
+352.17%
FY to Mar 2026 vs FY to Mar 2025
Net margin
23.6%
FY to Mar 2025: 5.9%

Financial data

Amounts in millions of JPY; per-share values in JPY; shares in millions.

ItemQ2 2025
Basic EPS28.21
Diluted EPS28.21
Average shares (basic)397
Average shares (diluted)397